In general, if the atoms that make up the ring contain heteroatoms, such rings become heterocycles, and organic compounds containing heterocycles are called heterocyclic compounds. An article called Comparing efficacy and side effects of two systemic chemotherapy regimens for eye-preserving therapy in children with retinoblastoma, published in 2022-02-28, which mentions a compound: 41575-94-4, Name is cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), Molecular C6H12N2O4Pt, Computed Properties of C6H12N2O4Pt.
Eye-preserving therapy in retinoblastoma comprises systemic chemotherapy, but studies analyzing the efficacy of different chemotherapy regimens are scarce. The efficacy and side effects of two different eye-preserving chemotherapy regimens containing either vincristine, etoposide, and carboplatin (VEC) or cyclophosphamide, vincristine, etoposide, and carboplatin (CyVEC) were compared in a prospective non-interventional observational study including children diagnosed with retinoblastoma between 2013 and 2019 in Germany and Austria. Event-free eye survival (EFES) and overall eye survival (OES) of all 164 eyes treated with both regimens and risk factors were investigated. The EFES after VEC (2-yr EFES 72.3) was higher than after CyVEC (2-yr EFES 50.4) (plogrank < .001). The OES did not differ significantly between the two treatment groups (plogrank = .77; 2-yr OES VEC: 82.1vs. CyVEC: 84.8). Advanced International Classification of Retinoblastoma (ICRB) group was prognostic for a lower EFES (plogrank < .0001; 2-yr EFES ICRB A/B/C 71.3vs. ICRB D/E 43.0) and OES (plogrank < .0001; 2-yr OES ICRB A/B/C 93.1vs. ICRB D/E 61.5). The multivariate anal. showed that age at diagnosis older than 12 mo and ICRB A/B/C were associated with better EFES. No second malignancies or ototoxicities were reported after a follow-up of median 3.1 years after diagnosis of retinoblastoma (range 0.1-6.9 years). Despite omitting cyclophosphamide, the EFES was higher after VEC chemotherapy that contains higher doses of carboplatin compared to CyVEC. The major risk factor for enucleation was advanced ICRB tumor grouping. Randomized clin. trials on efficacy and side effects of eye-preserving chemotherapy are required to tailor treatment protocols for retinoblastoma patients. There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Computed Properties of C6H12N2O4Pt, and with the development of science, more effects of this compound(41575-94-4) can be discovered.
Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics